Cargando…
MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2
MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who exper...
Autores principales: | Chen, Ming-Jenn, Wu, De-Wei, Wang, Gao-Chang, Wang, Yao-Chen, Chen, Chi-Yi, Lee, Huei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862613/ https://www.ncbi.nlm.nih.gov/pubmed/29568392 http://dx.doi.org/10.18632/oncotarget.24474 |
Ejemplares similares
-
A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop
por: Wu, De-Wei, et al.
Publicado: (2018) -
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2
por: Tung, Min-Che, et al.
Publicado: (2016) -
MicroRNA-630 suppresses tumor metastasis through the TGF-β- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma
por: Chen, Wei-xun, et al.
Publicado: (2016) -
Increased MicroRNA-630 Expression in Gastric Cancer Is Associated with Poor Overall Survival
por: Chu, Dake, et al.
Publicado: (2014) -
Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression
por: Rupaimoole, Rajesha, et al.
Publicado: (2016)